Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
In the vast majority of those infected with HIV virus who are untreated, there is
deterioration in immune health over a period of months or years inevitably leading to
full-blown AIDS and demise. Treatment with ARV's stop or slow down this deterioration if
started before a certain degree of progression occurs and has saved millions of lives. The
investigators' study hypothesis is that effectiveness of a very low dose of an FDA-approved
medication, naltrexone hydrochloride, (Low-Dose Naltrexone, or LDN) will compare favorably to
ARV's to prevent progression of HIV+ toward immune deterioration and full-blown AIDS.
Phase:
Phase 2
Details
Lead Sponsor:
The Ojai Foundation
Treatments:
Efavirenz Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Lamivudine Lopinavir Naltrexone Nevirapine Stavudine Stavudine, lamivudine, nevirapine drug combination Tenofovir